Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 1
1985 2
1986 2
1987 2
1988 7
1989 4
1990 3
1991 6
1992 6
1993 14
1994 3
1995 7
1996 4
1997 8
1998 2
1999 5
2000 12
2001 7
2002 6
2003 10
2004 6
2005 7
2006 6
2007 4
2008 10
2009 8
2010 6
2011 7
2012 5
2013 17
2014 21
2015 17
2016 22
2017 19
2018 50
2019 94
2020 34
Text availability
Article attribute
Article type
Publication date

Search Results

399 results
Results by year
Filters applied: . Clear all
Page 1
Clinical approach to the inflammatory etiology of cardiovascular diseases.
Ruscica M, Corsini A, Ferri N, Banach M, Sirtori CR. Ruscica M, et al. Pharmacol Res. 2020 May 20:104916. doi: 10.1016/j.phrs.2020.104916. Online ahead of print. Pharmacol Res. 2020. PMID: 32445957 Free PMC article. Review.
Finally, icosapent ethyl has been shown to reduce the CV risk in hypertriglyceridemia, with a 27% reduction of hsCRP. The inflammation-based approach to arterial disease has considerably gained from an improved understanding of the clinical diagnostic strategy and f …
Finally, icosapent ethyl has been shown to reduce the CV risk in hypertriglyceridemia, with a 27% reduction of hsCRP. The infl …
The return of triglycerides and revival of omega-3 fatty acids!
Ferrières J. Ferrières J. Arch Cardiovasc Dis. 2020 May 13:S1875-2136(20)30107-8. doi: 10.1016/j.acvd.2020.04.004. Online ahead of print. Arch Cardiovasc Dis. 2020. PMID: 32417104 No abstract available.
2019 clinical trials in lipid lowering.
Feldman DI, Pacor JM, Blumenthal RS, Nasir K. Feldman DI, et al. Curr Opin Cardiol. 2020 May 13. doi: 10.1097/HCO.0000000000000757. Online ahead of print. Curr Opin Cardiol. 2020. PMID: 32412963
Trials on previously studied therapies, such as PCSK9 inhibitors, and new therapies, including inclisiran, bempedoic acid and icosapent ethyl demonstrate significant potential for further lowering of LDL-C levels and risk for events on top of maximally tolera …
Trials on previously studied therapies, such as PCSK9 inhibitors, and new therapies, including inclisiran, bempedoic acid and icos
Omega-3 fatty acid therapy for cardiovascular disease: justified or not?
Maki KC, Dicklin MR. Maki KC, et al. Curr Opin Cardiol. 2020 May 13. doi: 10.1097/HCO.0000000000000741. Online ahead of print. Curr Opin Cardiol. 2020. PMID: 32412960
RECENT FINDINGS: Combined results from randomized controlled trials using low-dosage (≤1.8 g/day of ethyl esters) eicosapentaenoic acid (EPA) or EPA + docosahexaenoic acid (DHA) suggest a small benefit for reducing coronary heart disease risk. The Redu …
RECENT FINDINGS: Combined results from randomized controlled trials using low-dosage (≤1.8 g/day of ethyl esters) eicosapentaenoic
THE INTERPLAY BETWEEN CARDIOLOGY AND DIABETOLOGY: A RENEWED COLLABORATION TO OPTIMIZE CARDIOVASCULAR PREVENTION AND HEART FAILURE MANAGEMENT.
Sabouret P, Galati G, Angoulvant D, Germanova O, Castelletti S, Pathak A, Metra M, Margonato A. Sabouret P, et al. Eur Heart J Cardiovasc Pharmacother. 2020 May 13:pvaa051. doi: 10.1093/ehjcvp/pvaa051. Online ahead of print. Eur Heart J Cardiovasc Pharmacother. 2020. PMID: 32402065
A large number of randomized clinical trials and metanalyses provided strong evidence about therapeutic strategies acting on glucose metabolism such as GLP-1 RA and SGLT2i and about lipid-lowering treatment such as PCSK9i and Icosapent Ethyl. ...
A large number of randomized clinical trials and metanalyses provided strong evidence about therapeutic strategies acting on glucose metabol …
Approach to the Patient with Dyslipidemia.
Feingold KR. Feingold KR. 2020 May 11. In: Feingold KR, Anawalt B, Boyce A, Chrousos G, Dungan K, Grossman A, Hershman JM, Kaltsas G, Koch C, Kopp P, Korbonits M, McLachlan R, Morley JE, New M, Perreault L, Purnell J, Rebar R, Singer F, Trence DL, Vinik A, Wilson DP, editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000–. Endotext. 2000–. PMID: 26561696 Free Books & Documents. Review.
When LDL-C levels are at goal but triglyceride and non-HDL-C levels are still elevated recent data suggests further treatment with icosapent ethyl is beneficial. ...
When LDL-C levels are at goal but triglyceride and non-HDL-C levels are still elevated recent data suggests further treatment with icosap
Novel emerging therapies in atherosclerosis targeting lipid metabolism.
Gupta M, Blumenthal C, Chatterjee S, Bandyopadhyay D, Jain V, Lavie CJ, Virani SS, Ray KK, Aronow WS, Ghosh RK. Gupta M, et al. Expert Opin Investig Drugs. 2020 May 22:1-12. doi: 10.1080/13543784.2020.1764937. Online ahead of print. Expert Opin Investig Drugs. 2020. PMID: 32363959
We discuss other therapeutics such as lomitapide, mipomersen, volanesorsen, and evinacumab and newly approved non-statin-based therapies such as ezetimibe, icosapent ethyl (IPE), and bempedoic acid. ...Recently approved bempedoic acid/ezetimibe combina …
We discuss other therapeutics such as lomitapide, mipomersen, volanesorsen, and evinacumab and newly approved non-statin-based therapies suc …
Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014.
Fan W, Philip S, Granowitz C, Toth PP, Wong ND. Fan W, et al. Cardiol Ther. 2020 Jun;9(1):207-213. doi: 10.1007/s40119-020-00170-x. Epub 2020 Apr 23. Cardiol Ther. 2020. PMID: 32328971 Free PMC article.
Interventions such as icosapent ethyl that have been shown to reduce ASCVD event risk in this elevated TG population with type 2 diabetes or established ASCVD can provide substantial clinical benefit for these patients....
Interventions such as icosapent ethyl that have been shown to reduce ASCVD event risk in this elevated TG population with type …
399 results
Jump to page
Feedback